Categories: News

TERREPOWER Appoints Brandon Handy as Chief People Officer

DALLAS, Dec. 2, 2025 /PRNewswire/ — TERREPOWER today announced that Brandon Handy has been appointed Chief People Officer, effective immediately. This appointment marks a new level of senior leadership in a distinguished career.

- Advertisement -

“I am delighted to announce Brandon Handy’s appointment to Chief People Officer,” said Duncan Gillis, CEO of TERREPOWER. “Brandon has excelled in driving functional initiatives, ensuring strong governance, and elevating collaboration across both our corporate functions and business units. He has an unwavering commitment to our people‑first culture.”

- Advertisement -

Based at TERREPOWER’s Dallas, TX Corporate Center, Brandon joined the company as Vice President of Talent Management in 2022, bringing more than 16 years of experience in strategic HR leadership. Prior to joining TERREPOWER, he served as director of global human resources at Owens Corning, where he led HR process standardization, optimized talent initiatives, and developed inclusion and diversity programs. His extensive background also includes leadership roles at Trinity Industries, Kohl’s Department Stores and Pfizer, where he gained valuable experience in HR strategy, safety and business alignment.

- Advertisement -

Brandon earned both his bachelor’s degree in business administration and his MBA from Florida A&M University. He has earned HR certifications through both the HR Certification Institute and the Society for Human Resource Management, as well as a certification in Industrial Health and Safety from Georgia Tech.

- Advertisement -

“Brandon’s promotion to Chief People Officer is well-deserved,” said Gillis. “This appointment reflects our confidence in Brandon’s capacity to foster an inclusive, high-performing workplace in our facilities worldwide. His dedication to serving his internal customers has set a high standard, earning him a reputation for both excellence and reliability.”

- Advertisement -

About TERREPOWER

- Advertisement -

TERREPOWER, formerly BBB Industries, is the largest sustainable manufacturer in the world by volume. Founded in 1987 on a legacy of innovation, TERREPOWER is a global pure-play aftermarket leader specializing in providing high-quality components to the automotive and industrial markets. Based in Daphne, Alabama, TERREPOWER has a dedicated global workforce of over 10,000 employees and an extensive operational footprint throughout North America and Europe, including 19 sustainable manufacturing facilities, 14 distribution centers, and 28 brands with products sold in more than 90 countries. TERREPOWER is committed to strengthening supply chain resilience, reducing waste and advancing the circular economy. Learn more at www.terrepower.com.

- Advertisement -

Logo – https://mma.prnewswire.com/media/2337976/TERREPOWER1_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/terrepower-appoints-brandon-handy-as-chief-people-officer-302630096.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

7 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

7 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

7 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

7 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

7 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

7 hours ago